327 related articles for article (PubMed ID: 30470647)
41. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
[TBL] [Abstract][Full Text] [Related]
43. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
44. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation.
Seo KW; Kim BH; Park CH; Kim CI; Chang HS
Korean J Urol; 2010 Mar; 51(3):165-70. PubMed ID: 20414391
[TBL] [Abstract][Full Text] [Related]
45. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Fernandez-Gomez J; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Hernandez R; Madero R; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Isorna S; Rabadan M; Astobieta A; Montesinos M; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
Eur Urol; 2008 May; 53(5):992-1001. PubMed ID: 17950987
[TBL] [Abstract][Full Text] [Related]
47. Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.
Luitel BR; Chalise PR; Nathani S; Gupta DK; Subedi P; Chapagain S; Sharma UK; Gyawali PR; Shrestha GK; Joshi BR
Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):352-356. PubMed ID: 29371493
[TBL] [Abstract][Full Text] [Related]
48. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J;
Eur Urol; 2008 Aug; 54(2):303-14. PubMed ID: 18468779
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
[TBL] [Abstract][Full Text] [Related]
50. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Alfred Witjes J; Lebret T; Compérat EM; Cowan NC; De Santis M; Bruins HM; Hernández V; Espinós EL; Dunn J; Rouanne M; Neuzillet Y; Veskimäe E; van der Heijden AG; Gakis G; Ribal MJ
Eur Urol; 2017 Mar; 71(3):462-475. PubMed ID: 27375033
[TBL] [Abstract][Full Text] [Related]
51. Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer.
Holz S; Albisinni S; Gilsoul J; Pirson M; Duthie V; Quackels T; Vanden Bossche M; Roumeguère T
Res Rep Urol; 2017; 9():195-202. PubMed ID: 29034222
[TBL] [Abstract][Full Text] [Related]
52. Prediction models for progression of non-muscle-invasive bladder cancer: A review.
Fujii Y
Int J Urol; 2018 Mar; 25(3):212-218. PubMed ID: 29247553
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.
Plasek J; Weissert J; Downs T; Richards K; Ravvaz K
JMIR Cancer; 2021 Jun; 7(2):e25800. PubMed ID: 34156341
[TBL] [Abstract][Full Text] [Related]
54. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
[TBL] [Abstract][Full Text] [Related]
55. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
[TBL] [Abstract][Full Text] [Related]
56. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
[TBL] [Abstract][Full Text] [Related]
57. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
[No Abstract] [Full Text] [Related]
58. NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?
Lammers RJ; Sylvester RJ; Lee CT; Witjes JA
Urol Clin North Am; 2013 May; 40(2):155-64. PubMed ID: 23540774
[TBL] [Abstract][Full Text] [Related]
59. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
[TBL] [Abstract][Full Text] [Related]
60. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
